HexaBody-DR5/DR5 (GEN1029)

HexaBody®-DR5/DR5 (GEN1029) is a mixture of two non-competing HexaBody molecules that target two distinct epitopes on death receptor 5 (DR5), a cell surface receptor that mediates programmed cell death. Increased expression of DR5 has been reported in several types of tumors. HexaBody-DR5/DR5 is the first HexaBody molecule to enter the clinic. 

Clinical studies
A Phase I/II study is currently ongoing in a variety of solid tumors.